JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

CPA4 overexpression correlates with poor prognosis and tumor progression in endometrial cancer

  • 0Department of Rehabilitation, School of Nursing, Jilin University, Changchun, 130021, China.
European Journal of Medical Research +

|

March 16, 2025

|

March 16, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Carboxypeptidase A4 (CPA4) is overexpressed in endometrial cancer, correlating with tumor progression. This study identifies CPA4 as a promising biomarker for improved diagnosis and prognosis in endometrial cancer patients.

Area Of Science

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background

  • Rising global endometrial cancer rates necessitate advanced diagnostic tools and novel biomarkers.
  • Carboxypeptidase A4 (CPA4) is implicated in cancer development but unstudied in endometrial cancer.

Purpose Of The Study

  • To investigate the role of CPA4 in endometrial cancer.
  • To evaluate CPA4 as a diagnostic and prognostic biomarker.

Main Methods

  • Analysis of CPA4 mRNA expression in TCGA and GEO databases.
  • Immunohistochemical validation in 116 clinical endometrial cancer samples.
  • Functional studies in Ishikawa and Hec-1-A cell lines.
  • Bioinformatic analyses including GO, KEGG, GSEA, and survival analysis.
  • Development of a clinical prognostic nomogram model.

Main Results

  • CPA4 is significantly overexpressed in endometrial cancer tissues compared to normal tissues.
  • CPA4 overexpression correlates with advanced tumor stage and poorer patient prognosis.
  • Functional assays demonstrated that CPA4 inhibition reduces tumor cell proliferation and metastasis.
  • Survival analyses and the developed nomogram confirmed CPA4's prognostic value.

Conclusions

  • CPA4 is a significant biomarker for endometrial cancer diagnosis and prognosis.
  • CPA4 represents a potential novel therapeutic target and clinical tool for improved patient management.

Keywords:

Related Concept Videos

Tumor Progression 02:07

6.2K

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Abnormal Proliferation 02:23

4.4K

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

mTOR Signaling and Cancer Progression 03:03

3.7K

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...